A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Key facts

Sponsor

BeiGene

Principal Investigator

Study Director

BeiGene

Intervention

BG-60366(drug)

Enrollment

93 target

Eligibility

18 years · All sexes

Timeline

2024 – 2028

Study locations (28)

• University of Colorado, Denver, Colorado, United States
• Dana Farber Cancer Institute, Boston, Massachusetts, United States
• Washington University School of Medicine Siteman Cancer Center, St Louis, Missouri, United States
• Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
• Ohio State University, Columbus, Ohio, United States
• The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
• Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
• Liverpool Hospital, Liverpool, New South Wales, Australia
• Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
• Cancer Research South Australia, Adelaide, South Australia, Australia
• Austin Health, Heidelberg, Victoria, Australia
• Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
• Beijing Cancer Hospital, Beijing, Beijing Municipality, China
• Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou, Guangdong, China
• The Tumor Hospital Affiliated to Guangxi Medical Universitywuxiang Branch, Nanning, Guangxi, China
• +13 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE1NCT07348211
  First in Human Study of SIM0610 in Solid Tumors
  Jiangsu Simcere Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE3NCT07185997
  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
  ArriVent BioPharma, Inc.

See all trials for Small cell lung cancer →